Sarepta therapeutics and genevant sciences announce research collaboration for lipid nanoparticle-based gene editing therapeutics

-- alliance will assess the use of sarepta's proprietary gene editing technology and genevant's proprietary lnp delivery platform for multiple neuromuscular targets -- -- sarepta to have options for an exclusive license to genevant's lnp technology for four neuromuscular indications --
SRPT Ratings Summary
SRPT Quant Ranking